Trial · NCT03298698
Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome
NCT03298698, Phase 3, Unknown, Radboud University Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome. Trials, record NCT03298698. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03298698
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome
- NCT number
- NCT03298698
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Radboud University Medical Center
- Conditions
- Idiopathic Nephrotic Syndrome, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Interventions
- Rituximab, Prednisone
- First posted
- 2017-10-02
- Last updated
- 2018-08-27
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete remission | 8 weeks | The proportion of patients reaching complete remission defined as proteinuria \<0.3 g/day or \< 300 mg/g |
| Secondary | Partial remission | 8 weeks | The proportion of patients reaching partial remission defined as proteinuria \< 3.5 g/24 h or \< 3.5 g/g and 50% lower than baseline proteinuria |
| Secondary | Late complete or partial remission | 2-12 months | The proportion of patients reaching complete remission defined as proteinuria \<0.3 g/day or \< 300 mg/g or The proportion of patients reaching partial remission defined as proteinuria \< 3.5 g/24 h or \< 3500 mg/g and 50% lower than baseline proteinuria |
| Secondary | Time to remission | 12 months | Time between start of treatment and reaching partial or complete remission |
| Secondary | Time to relapse | 12 months | The time between partial or complete remission and relapse (defined as urinary protein excretion to ≥3.5 g/24 h or ≥3.5 g/g creatinine |
| Secondary | Proportion of patients with a relapse | 12 months | The proportion of patients with relapse (defined as urinary protein excretion to ≥3.5 g/24 h or ≥3.5 g/g creatinine in patients who had at least attained a partial remission and the time to relapse |
| Secondary | Proportion of patients treated with additional immunosuppressive drugs | 12 months | Proportion of patients treated with immunosuppressive drugs other than the assigned treatment with rituximab or prednisolone |
| Secondary | General health assessment | at 2, 6, 9 and 12 months | Difference in general health measured by RAND-36 |
| Secondary | Quality of life measured with TAAQOL | at 2, 6, 9 and 12 months | Difference in quality of life measured with TNO-academisch Ziekenhuis Leiden Questionnaire for Adult's Health-Difference in Quality of Life |
| Secondary | Proportion of patients with adverse events | at 2 and 12 months | The proportion of patients with adverse events. Adverse events graded according to Common Terminology Criteria For Adverse Events (NCI-CTCAE v4.03) |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03298698
GET https://conductscience.org/api/trials/v1/NCT03298698/registered